LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 278 of 535
Next
>>
>
6926 to 6950 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	JW-7-24-1	3.33	uM	LJP6	2	B20	72	hr	1097	1958	3713	0.5272	0.3899
BT-20	JW-7-24-1	3.33	uM	LJP6	3	B20	72	hr	1097	1743	3696	0.4715	0.3023
BT-20	JW-7-24-1	10	uM	LJP6	1	B19	72	hr	1097	678	3610	0.1878	-0.2443
BT-20	JW-7-24-1	10	uM	LJP6	2	B19	72	hr	1097	744	3713	0.2003	-0.1982
BT-20	JW-7-24-1	10	uM	LJP6	3	B19	72	hr	1097	701	3696	0.1896	-0.2256
BT-20	Dasatinib	0.04	uM	LJP6	1	I06	72	hr	1097	1559	3610	0.4318	0.2268
BT-20	Dasatinib	0.04	uM	LJP6	2	I06	72	hr	1097	1550	3713	0.4174	0.2170
BT-20	Dasatinib	0.04	uM	LJP6	3	I06	72	hr	1097	1704	3696	0.4610	0.2856
BT-20	Dasatinib	0.04	uM	LJP5	1	D06	72	hr	1097	3074	3735	0.8230	0.7912
BT-20	Dasatinib	0.04	uM	LJP5	2	D06	72	hr	1097	3202	3877	0.8257	0.8004
BT-20	Dasatinib	0.04	uM	LJP5	3	D06	72	hr	1097	2951	3925	0.7518	0.7126
BT-20	Dasatinib	0.12	uM	LJP6	1	I05	72	hr	1097	1486	3610	0.4116	0.1930
BT-20	Dasatinib	0.12	uM	LJP6	2	I05	72	hr	1097	1531	3713	0.4123	0.2085
BT-20	Dasatinib	0.12	uM	LJP6	3	I05	72	hr	1097	1350	3696	0.3652	0.1256
BT-20	Dasatinib	0.12	uM	LJP5	1	D05	72	hr	1097	2183	3735	0.5844	0.4759
BT-20	Dasatinib	0.12	uM	LJP5	2	D05	72	hr	1097	2080	3877	0.5364	0.4207
BT-20	Dasatinib	0.12	uM	LJP5	3	D05	72	hr	1097	2656	3925	0.6766	0.6172
BT-20	Dasatinib	0.37	uM	LJP6	1	I04	72	hr	1097	1177	3610	0.3260	0.0417
BT-20	Dasatinib	0.37	uM	LJP6	2	I04	72	hr	1097	1009	3713	0.2717	-0.0466
BT-20	Dasatinib	0.37	uM	LJP6	3	I04	72	hr	1097	1142	3696	0.3090	0.0231
BT-20	Dasatinib	0.37	uM	LJP5	1	D04	72	hr	1097	1401	3735	0.3751	0.1483
BT-20	Dasatinib	0.37	uM	LJP5	2	D04	72	hr	1097	1623	3877	0.4185	0.2398
BT-20	Dasatinib	0.37	uM	LJP5	3	D04	72	hr	1097	1365	3925	0.3477	0.1261
BT-20	Dasatinib	1.11	uM	LJP6	1	I03	72	hr	1097	1026	3610	0.2842	-0.0383
BT-20	Dasatinib	1.11	uM	LJP6	2	I03	72	hr	1097	1141	3713	0.3072	0.0225

|<
<<
Previous
Page 278 of 535
Next
>>
>
6926 to 6950 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)